Navigation Links
Surgex(TM) Fuels 2008 San Luis Potosi Open Champion Russell Surber Through Grueling 36 Hole Final Day
Date:5/28/2008

Wins First Canadian Golf Tour Title While Wearing Surgex(TM) Branded

Apparel

BASKING RIDGE, N.J., May 28 /PRNewswire-FirstCall/ -- Russell Surber overcame a virus and a late bogey to capture his first Canadian Tour title at the San Luis Potosi Open by two strokes over Adam Bland and Wil Collins. The victory places the former University of Texas standout in prime position to qualify for the PGA's RBC Canadian Open held in July. An avid strength and conditioning advocate, Surber relies on Surgex(TM) sports nutritional formula to help accelerate his recovery from workouts and long hours on the course.

Surber stated, "Drinking Surgex(TM) leading up to and through this week's tournament definitely helped me fight through a challenging final 36 holes. Strength and endurance training has become an integral part of my tournament preparations and using Surgex(TM) this season has helped my golf game tremendously."

Surber's decision to train with Surgex(TM) is another example of the growing trend amongst many professional athletes and teams using Millennium's clinically validated sports drink to assist in their strength and recovery. Russell will look to keep his stellar play going when he competes in this week's Spring Qualifying School in British Columbia, Vancouver. Many of today's well known players including Chris DiMarco, Tim Herron and Mike Weir used this prominent event to springboard themselves to very successful careers on the PGA Tour.

About SURGEX(TM):

SURGEX(TM) (http://www.surgexsports.com) was created from Millennium's extensive experience providing advanced nutritional formulas to some of the most prestigious medical institutions throughout the United States. The proprietary SURGEX(TM) formula intends to meet the growing demand of professional, amateur, and Olympic athletes as well as their coaches looking for nutritional support in a marketplace dominated by products with no clinical proof of benefit, unsubstantiated claims, excess protein, stimulants, and banned substances.

In double blind placebo controlled clinical trials conducted at the Rutgers University Human Performance Lab SURGEX(TM) significantly outperformed leading competitive products by assisting in reducing the damaging effects of exercise. SURGEX(TM) proved to be a superior product by improving peak power outputs, lowering oxidative stress/inflammatory markers, reducing fatigue (poor energy recovery) and the breakdown of muscle (post exercise wasting), as well as reducing free radical production (oxidative stress). The formula meets NCAA guidelines for use by collegiate athletes and is certified by The Banned Substances Control Group (BSCG) to contain no banned substances.

Statements in this news release regarding future financial and operating results, future growth in R&D programs, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of the Company's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the Securities and Exchange Commission ("SEC"). These statements have not been evaluated by the Food and Drug Administration. SURGEX(TM) is not intended to diagnose, treat, cure, or prevent and disease.

Contact: John Swon, 908-604-2500


'/>"/>
SOURCE Millennium Biotechnologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. SURGEX(TM) Joins the Team of Sponsors for the PGA Tours 2008 Arnold Palmer Invitational Presented by MasterCard
2. Calorie restriction inhibits, obesity fuels development of epithelial cancers
3. Calorie restriction limits Calorie restriction inhibits, obesity fuels development of epithelial can
4. Calorie restriction limits and obesity fuels development of epithelial cancers
5. CompareNetworks, Inc. Fuels Growth by Raising Round of Financing
6. Researchers identify and shut down protein that fuels ovarian cancer
7. NexGen Biofuels Ltd Announces the Change of its Symbol to "NXGN"
8. Medicare Drug Plan Fuels Health-Care Spending
9. OHSU Cancer Institute researcher discovers what fuels certain cancer mutation
10. Healthcare Technologies Announces New Date for the Shareholders Meeting to Approve the Nexgen Biofuels Transaction
11. Healthcare Technologies to Reschedule the Shareholders Meeting to Approve the NexGen Biofuels Transaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology: